Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma

Our analytical model may be useful in predicting lower RR in patients with ILC. If validated, this provides a faster and less expensive alternative to Oncotype DX testing in certain patients with ILC.